G Protein News and Research

RSS

Noninvasive tool created to detect pancreatic cancer through risk assessment test using saliva

Pancreatic cancer is one of the deadliest forms of cancer. Most of those with the disease will die within the first year of diagnosis, and just 6 percent will survive five years.

10 Oct 2013

Scientists create model in battle against adenomyosis

For the first time, researchers have created a model that could help unlock what causes adenomyosis, a common gynecological disease that is a major contributor to women having to undergo hysterectomies.

10 Oct 2013

Research points to causes, potential treatment approaches for systemic sclerosis

Using mice, lab-grown cells and clues from a related disorder, Johns Hopkins researchers have greatly increased understanding of the causes of systemic sclerosis, showing that a critical culprit is a defect in the way certain cells communicate with their structural scaffolding

10 Oct 2013

Key findings may have broad implications for future scleroderma therapy

The Scleroderma Research Foundation today said that researchers at The Johns Hopkins University working in a novel mouse model of Stiff Skin Syndrome have made key discoveries that may have broad implications for future scleroderma therapy.

10 Oct 2013

Mechanism preserving genome integrity help develop new therapies against DiGeorge syndrome

An international team of scientists-including researchers at GENYO, the Centre for Genomics and Oncological Research (Pfizer-University of Granada- Andalusian Regional Government)-has described a molecular mechanism that facilitates the defence of the human genome against "bombarding" by mobile DNA sequences.

10 Oct 2013

People with high amounts of abdominal fat are likely to develop memory loss

Although problems with memory become increasingly common as people age, in some persons, memories last long time, even a life time. On the other hand, some people experience milder to substantial memory problems even at an earlier age.

10 Oct 2013

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that it has initiated a Phase 2 clinical trial to evaluate PRM-151, its lead product candidate, in patients with myelofibrosis.

10 Oct 2013

Thwarting Greatwall May Trigger Mitotic Collapse And Suppress Tumor Development

...

9 Oct 2013

U.S. Army Grants QR Pharma, UCLA $3M To Test TBI Treatment

...

9 Oct 2013

Compugen drug candidate prevents autoimmune type I diabetes in animal model

Compugen Ltd., announced today that CGEN-15001, an Fc fusion protein drug candidate derived from a novel immune checkpoint protein discovered by Compugen, has been shown to be highly efficient in preventing the development of disease in a well-accepted animal model of autoimmune type I diabetes, known also as juvenile diabetes.

9 Oct 2013

Study points to new pathways, targets for novel therapies to treat neurodegenerative diseases

Scientists at the Montreal Neurological Institute and Hospital-The Neuro, McGill University, have made important discoveries about a cellular process that occurs during normal brain development and may play an important role in neurodegenerative diseases.

9 Oct 2013

Molecular Templates secures $8.5M series C financing plus $10.6M grant from CPRIT

Molecular Templates, Inc., a biopharmaceutical company focused on the discovery and development of a new class of biologic therapeutics, announced today that it recently secured an $8.5M series C financing led by Excel Venture Management. Santé Ventures, an existing investor, also participated in the round.

9 Oct 2013

Research on flaviviruses could help in developing effective therapies for persistent infections

We generally do not devote much time to worrying about the problems faced by viruses, although understanding them may provide clues on how to combat diseases.

9 Oct 2013

Research suggests almonds may be good snack option for those concerned about weight

A new study published in the October issue of the European Journal of Clinical Nutrition found that study participants eating 1.5 ounces of dry-roasted, lightly salted almonds every day experienced reduced hunger and improved dietary vitamin E and monounsaturated ("good") fat intake without increasing body weight.

9 Oct 2013

New method for improving cord blood transplant success

Starting with a discovery in zebrafish in 2007, Harvard Stem Cell Institute researchers have published initial results of a Phase Ib human clinical trial of a therapeutic that has the potential to improve the success of blood stem cell transplantation.

9 Oct 2013

Three Penn Medicine researchers awarded grants for neuromuscular disease research

The Muscular Dystrophy Association has awarded research grants totaling over $1,000,000 to three Penn Medicine researchers: James Shorter, PhD, associate professor of Biochemistry and Biophysics; Hansell Stedman, MD, associate professor of Surgery; and Lee Sweeney, PhD, director of the Center for Orphan Disease Research and Therapy.

9 Oct 2013

CNIO researcher identifies new molecular mechanism that regulates genome stability, cell proliferation

Cell division is an essential process for the development of an organism. This process, however, can cause tumour growth when it stops working properly. Tumour cells accumulate alterations in their genetic material, and this makes them divide in an uncontrolled fashion, thus encouraging growth of the tumour.

9 Oct 2013

Study: Distinct behavior of proteins reflects common biochemical principles

Researchers from Case Western Reserve University School of Medicine have found unexpected similarities between proteins that were thought to be fundamentally different.

9 Oct 2013

Two gene mutations associated with increased risk of developing eating disorders

Eating disorders like anorexia nervosa and bulimia often run in families, but identifying specific genes that increase a person's risk for these complex disorders has proved difficult.

9 Oct 2013

Edimer doses first XLHED-affected neonate in Phase 2 trial of EDI200

Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced the enrollment and completed dosing of the first XLHED-affected neonate in a Phase 2 trial of EDI200, the company's novel, proprietary, recombinant protein.

9 Oct 2013

G Protein News and Research

Noninvasive tool created to detect pancreatic cancer through risk assessment test using saliva

Scientists create model in battle against adenomyosis

Research points to causes, potential treatment approaches for systemic sclerosis

Key findings may have broad implications for future scleroderma therapy

Mechanism preserving genome integrity help develop new therapies against DiGeorge syndrome

People with high amounts of abdominal fat are likely to develop memory loss

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Thwarting Greatwall May Trigger Mitotic Collapse And Suppress Tumor Development

U.S. Army Grants QR Pharma, UCLA $3M To Test TBI Treatment

Compugen drug candidate prevents autoimmune type I diabetes in animal model

Study points to new pathways, targets for novel therapies to treat neurodegenerative diseases

Molecular Templates secures $8.5M series C financing plus $10.6M grant from CPRIT

Research on flaviviruses could help in developing effective therapies for persistent infections

Research suggests almonds may be good snack option for those concerned about weight

New method for improving cord blood transplant success

Three Penn Medicine researchers awarded grants for neuromuscular disease research

CNIO researcher identifies new molecular mechanism that regulates genome stability, cell proliferation

Study: Distinct behavior of proteins reflects common biochemical principles

Two gene mutations associated with increased risk of developing eating disorders

Edimer doses first XLHED-affected neonate in Phase 2 trial of EDI200

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News